Medical/Pharmaceuticals

Ping An Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, with Profitability Accelerating

Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health" or "the Company", Stock Code: 1833.HK) announced its first-quarter results for...

2025-04-24 15:30 3601

Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage

- Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA models featured in two peer-reviewed articles - - New data on MM-II to be presented this weekend at the OARSI 2025 World Conference on Osteoarthritis - - MM-II recently granted Fast Track Designation ...

2025-04-24 14:31 2255

CGBIO Receives FDA IDE Approval for NOVOSIS PUTTY, Advancing Toward U.S. Market Entry

- The bone graft incorporating rhBMP-2 has received FDA IDE approval for a pivotal clinical trial in spinal fusion - Positioned for global expansion in $750M spinal bone graft market SEOUL, South Korea, April 23, 2025 /PRNewswire/ -- CGBIO(CEO Hyun Seung Yu), a leading Korean company specializing...

2025-04-24 00:00 2871

SimonMed Imaging Partners with Lunit to Deliver Best-in-Class AI for Breast Cancer Detection

A Major Leap Forward in Patient Health and the Future of Mammography PHOENIX, April 23, 2025 /PRNewswire/ -- SimonMed Imaging®, one of the largest and most advanced outpatient medical imaging providers inthe United States, is proud to announce their partnership with Lunit, a global leader in AI-d...

2025-04-24 00:00 2539

LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)

Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING, April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeti...

2025-04-23 21:35 2498

Tsingke Gene Leads a Delivery Revolution with "Calendar Day Delivery"

BEIJING, April 23, 2025 /PRNewswire/ -- In March 2025, Tsingke pioneered the industry's first full-range "Calendar Day Delivery" model, redefining standards for gene synthesis services through a comprehensive suite of offerings such asTsynth™Gene Synthesis

2025-04-23 17:18 1948

A Breakthrough in Brain Surgery Monitoring: Guarding Lives with Raytron's Thermal Imaging Technology

YANTAI, China, April 23, 2025 /PRNewswire/ -- In high-stakes neurosurgery, gaining real-time insights into cerebral blood flow is vital yet challenging. Conventional indocyanine green (ICG) fluorescence imaging relies on contrast agents and offers limited repeatability. Now, infrared thermography...

2025-04-23 15:20 2210

Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

HANGZHOU, China, April 22, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeti...

2025-04-23 15:03 1914

Samsung Biologics reports first quarter 2025 financial results

* Recorded Q1'25 consolidated revenue of KRW 1.3 trillion * Recorded Q1'25 consolidated operating profit of KRW 486.7 billion * Company expected to maintain steady growth momentum in 2025 driven by enhanced operational efficiency and diverse service offerings INCHEON, South Korea, April 23, ...

2025-04-23 14:46 2681

VARON Advocates for Sustainability on Earth Day with Eco-Friendly Oxygen Solutions

NEW YORK, April 22, 2025 /PRNewswire/ -- This Earth Day, VARON is proud to reaffirm its commitment to both respiratory health and environmental responsibility. As a global leader in oxygen concentrator technology, VARON continues to advance sustainable innovation, offerin...

2025-04-23 08:11 3823

FDA Grants Authorisation for Minder®, the First and Only Implantable Continuous EEG Monitor Approved in US

*  The Australian-developed Minder system is an implantable device for continuous monitoring of brain activity in patients with epilepsy, developed to address the shortcomings in current electroencephalogram technologies *  The FDA has granted authorisation for Minder under its De Novo pathway...

2025-04-23 06:15 1959

WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year

* Firm commitment to tackling climate change in support of United Nations Sustainable Development Goals * Earth Day 2025 - Our Power, Our Planet, Contribute to a sustainable future SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Resear...

2025-04-22 16:30 4225

BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (Nasdaq: BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 3...

2025-04-21 20:30 3746

UK Clinical Study Finds Sky Labs' Smart Ring 'CART-I' More Sensitive Than Apple Watch for AFib Detection

* Published in the international journal Heart Rhythm O2, the clinical study demonstrates that CART-I achieved 84.6% sensitivity – higher than Apple Watch's 69.1% * Sky Labs also recognized with Korea's top tech honor: IR52 Jang Young-sil Award – Prime Minister's Award SEOUL, South Korea, Ap...

2025-04-21 20:00 2360

INTCO Medical Launches New Syntex™ Synthetic Disposable Latex Gloves Featuring Breakthrough Performance Beyond Natural Latex

ZIBO, China, April 21, 2025 /PRNewswire/ -- INTCO Medical ("INTCO" or "the Company"), the world's leading manufacturer of disposable gloves, has announced the global launch of its exclusive patentedSyntex™ Synthetic Disposable Latex Gloves  product. Breaki...

2025-04-21 19:15 2444

Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025

ALAMEDA, Calif. and TAIPEI, April 21, 2025 /PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will be featured at the American Associatio...

2025-04-21 19:00 2126

DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies

SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell therapy firm, for the tumor antigen-specific anti...

2025-04-21 15:35 2289

Declaration on longevity and precision medicine launched at Abu Dhabi Global Health Week

* Establishing actionable frameworks to advance precision medicine and longevity science * The declaration highlights the impact longevity and precision medicine can have on supporting healthy communities, and engages leaders to work towards actionable solutions, drive consensus among global ...

2025-04-19 00:36 3986

Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch

SHANGHAI, April 18, 2025 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2024 Annual Report, highlighting a bold and determined journey forward. With a specialty pharma strategy and operational efficiency, the company exceeded its commercialization targets and advanced its innovative p...

2025-04-18 22:10 3941

Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis

HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National Medical Products Administration (NMPA) for the tre...

2025-04-18 19:39 3453
1 ... 41424344454647 ... 250

Week's Top Stories